Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE: Regorafenib + Metronomic Chemotherapy in Metastatic Colorectal Cancer
NCT06425133Phase 2Recruiting
- Sponsor
- CHU de Besançon
- Start
- Jul 2024
- Primary completion
- Sep 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine, cyclophosphamide and aspirin in colorectal cancer (CRC) (2 arms), sponsored by CHU de Besançon. Primary endpoint: Progression-Free Survival at 5 months. Started Jul 2024; status: recruiting.
02
Drugs
capecitabinecyclophosphamideaspirin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06425133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06425133.